These two patents are said to cover the basic composition of viral particles resulting from Lipid Sciences’s proprietary viral delipidation process.
Lewis Meyer, president and CEO of Lipid Sciences, said: “The validation by the US Patent and Trademark Office of the novelty of Lipid Sciences’s viral delipidation as a technique for vaccine development not only represents a new direction in HIV vaccine research but also adds important assets to Lipid Sciences’s broad base of intellectual property.”